General Oncology

General Oncology is an emerging biotech focused on metastatic cancers with high unmet need, originating from a compelling n-of-1 case of a BRCA2+ pancreatic cancer patient treated successfully with melphalan. The company's lead asset, GO-4305C, reported a median progression-free survival of 14.2 months in a 12-patient Phase 1 trial (SHARON) in stage IV BRCA-associated pancreatic ductal adenocarcinoma, with two patients remaining disease-free for over 2.5 years. With a preclinical ophthalmology program in development and a lean team, the company is advancing its novel, multi-modal therapeutic approach while seeking to validate its platform in larger studies.

Design of multi-modal small molecule therapies using synergistic drug interactions to produce multiple independent mechanisms of action, aiming to overcome tumor drug resistance and minimize chronic toxicity.

In pancreatic cancer, GO-4305C will compete with standard chemotherapies (e.g., FOLFIRINOX, gemcitabine/nab-paclitaxel) and emerging targeted therapies for genetic subsets. In wet AMD, it would enter a market dominated by highly effective anti-VEGF biologics (e.g., aflibercept, ranibizumab, bevacizumab) and newer long-acting agents, requiring a clear differentiation in efficacy, safety, or convenience.